BIOA BioAge Labs, Inc.
Legal ·
BioAge Labs' 10-Q says a federal court dismissed the IPO securities class action with prejudice on March 2, 2026, and the plaintiff has appealed to the Ninth Circuit. The defendants are BioAge, its directors and certain officers, and the filings do not name the officers.
BioAge Labs priced 5.9 million shares with Goldman Sachs, Piper Sandler and Citigroup nine days after new phase 1 data on BGE-102, its brain-penetrant NLRP3 inhibitor.
BioAge Labs is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases by targeting the biology of human aging. Its lead program is BGE-102, an orally available, brain-penetrant small-molecule NLRP3 inhibitor. The first therapeutic area for BGE-102 is cardiometabolic disease, with a focus on atherosclerotic cardiovascular disease risk reduction through lowering chronic systemic inflammation measured by high-sensitivity C-reactive protein. BGE-102 was well-tolerated in the single ascending dose and initial multiple ascending dose cohorts, and the company plans a Phase 2a proof-of-concept trial in patients with obesity and elevated hsCRP. The second area is ophthalmology, starting with diabetic macular edema. BioAge is also developing apelin receptor APJ agonists for obesity, and in June 2025 it announced an option agreement with JiKang Therapeutics for a novel APJ agonist antibody. Its platform draws on proprietary longitudinal human datasets built from serial biobanked samples. Its collaborations include Eli Lilly, for platform-derived programs in molecule discovery, and Novartis, for an ongoing target discovery collaboration.
| Product or program | What it is | Stage |
|---|---|---|
| BGE-102 | Oral brain-penetrant NLRP3 inhibitor for cardiometabolic disease and diabetic macular edema | Phase 1 single and initial multiple ascending dose cohorts; Phase 2a planned |
| APJ agonists | Apelin receptor agonists for obesity, oral and subcutaneous programs | preclinical |
| Platform-derived programs (Eli Lilly collaboration) | Targets from the BioAge platform for cardiometabolic disease | molecule discovery |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $9.0 million | $0 |
| Research and development | $74.0 million | $59.0 million |
| Net income (loss) | -$80.6 million | -$71.1 million |
| Cash from operations | -$81.6 million | -$51.5 million |
| Cash and equivalents | $188.9 million | $354.3 million |
| Short-term investments | $92.2 million | $0 |
Our latest story on this, dated Aug 5, 2026: "BioAge faces Ninth Circuit appeal of dismissed IPO securities class action". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 5, 2026: "BioAge faces Ninth Circuit appeal of dismissed IPO securities class action". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jan 21, 2026: "BioAge sells $115 million of stock at $19.50 after NLRP3 pill cuts CRP 86% in obese patients". The story links the filing or release it is based on. Read the story.
BioAge Labs, Inc. trades under the ticker BIOA on NASDAQ.
BioAge Labs, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:Y7G; LS:A40D7P; LSX:A40D7P.
The SEC Central Index Key (CIK) for BioAge Labs, Inc. is 1709941. Its filings are on SEC EDGAR.
45,896,909 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05.
Our directory records BioAge Labs, Inc. under United States.
Our directory classifies BioAge Labs, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for BioAge Labs, Inc. is US09077V1008.
aibio.space lists BioAge Labs, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
BioAge Labs is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases by targeting the biology of human aging. Its lead program is BGE-102, an orally available, brain-penetrant small-molecule NLRP3 inhibitor.
BGE-102: Oral brain-penetrant NLRP3 inhibitor for cardiometabolic disease and diabetic macular edema Stage: Phase 1 single and initial multiple ascending dose cohorts; Phase 2a planned.
APJ agonists: Apelin receptor agonists for obesity, oral and subcutaneous programs Stage: preclinical.
Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. Source
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio